Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
Total Valuation
Nektar Therapeutics has a market cap or net worth of $547.35M. The enterprise value is $364.84M.
Market Cap$547.35M
Enterprise Value$364.84M
Share Statistics
Nektar Therapeutics has 19,018,574 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,018,574
Owned by Insiders1.09%
Owned by Institutions28.13%
Financial Efficiency
Nektar Therapeutics’s return on equity (ROE) is -1.96 and return on invested capital (ROIC) is -40.02%.
Return on Equity (ROE)-1.96
Return on Assets (ROA)-0.39
Return on Invested Capital (ROIC)-40.02%
Return on Capital Employed (ROCE)-0.43
Revenue Per Employee1.61M
Profits Per Employee-1.95M
Employee Count61
Asset Turnover0.32
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nektar Therapeutics is ―. Nektar Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value3.15
Price to FCF―
Price to Operating Cash Flow-1.96
PEG Ratio―
Income Statement
In the last 12 months, Nektar Therapeutics had revenue of 98.43M and earned -118.96M in profits. Earnings per share was -8.68.
Revenue98.43M
Gross Profit67.74M
Operating Income-105.20M
Pretax Income-119.20M
Net Income-118.96M
EBITDA-86.70M
Earnings Per Share (EPS)-8.68
Cash Flow
In the last 12 months, operating cash flow was -184.91M and capital expenditures -1.16M, giving a free cash flow of -186.07M billion.
Operating Cash Flow-184.91M
Free Cash Flow-186.07M
Free Cash Flow per Share-9.78
Dividends & Yields
Nektar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.76
52-Week Price Change52.28%
50-Day Moving Average23.32
200-Day Moving Average15.38
Relative Strength Index (RSI)66.82
Average Volume (3m)748.65K
Important Dates
Nektar Therapeutics upcoming earnings date is Nov 6, 2025, After Close (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date―
Financial Position
Nektar Therapeutics as a current ratio of 4.26, with Debt / Equity ratio of -397.16%
Current Ratio4.26
Quick Ratio4.26
Debt to Market Cap0.48
Net Debt to EBITDA-0.67
Interest Coverage Ratio-3.74
Taxes
In the past 12 months, Nektar Therapeutics has paid -239.00K in taxes.
Income Tax-239.00K
Effective Tax Rate<0.01
Enterprise Valuation
Nektar Therapeutics EV to EBITDA ratio is -2.88, with an EV/FCF ratio of -1.41.
EV to Sales2.54
EV to EBITDA-2.88
EV to Free Cash Flow-1.41
EV to Operating Cash Flow-1.42
Balance Sheet
Nektar Therapeutics has $175.90M in cash and marketable securities with $96.16M in debt, giving a net cash position of -$79.75M billion.
Cash & Marketable Securities$175.90M
Total Debt$96.16M
Net Cash-$79.75M
Net Cash Per Share-$4.19
Tangible Book Value Per Share$4.43
Margins
Gross margin is 83.15%, with operating margin of -106.88%, and net profit margin of -120.86%.
Gross Margin83.15%
Operating Margin-106.88%
Pretax Margin-121.10%
Net Profit Margin-120.86%
EBITDA Margin-88.08%
EBIT Margin-92.54%
Analyst Forecast
The average price target for Nektar Therapeutics is $96.17, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$96.17
Price Target Upside234.16% Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast-19.56%
EPS Growth Forecast35.55%